Patents by Inventor Michael L. Gosselin

Michael L. Gosselin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding anti-TREM-1 antibodies
    Patent number: 11952420
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: April 9, 2024
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Achal Pashine, Michael L Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
  • Anti-TREM-1 antibodies and uses thereof
    Patent number: 11919954
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: March 5, 2024
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
  • FAST-OFF RATE SERUM ALBUMIN BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20230145413
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: July 25, 2022
    Publication date: May 11, 2023
    Inventors: Stanley Richard KRYSTEK, Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Juhi JUNEJA
  • Fast-off rate serum albumin binding fibronectin type III domains
    Patent number: 11434275
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: September 6, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stanley Richard Krystek, Jr., Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Juhi Juneja
  • SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20220204589
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: November 16, 2021
    Publication date: June 30, 2022
    Inventors: Tracy S. MITCHELL, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan H. Davis, David Fabrizio
  • ANTI-TREM-1 ANTIBODIES AND USES THEREOF
    Publication number: 20220002404
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TRENT-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 6, 2022
    Inventors: Achal PASHINE, Michael L. GOSSELIN, Aaron P. YAMNIUK, Derek A. HOLMES, Guodong CHEN, Priyanka Apurva MADIA, Richard Yu-Cheng HUANG, Stephen Michael CARL
  • ANTI-TREM-1 ANTIBODIES AND USES THEREOF
    Publication number: 20210403561
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TRENT-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Application
    Filed: September 10, 2021
    Publication date: December 30, 2021
    Inventors: Achal PASHINE, Michael L. GOSSELIN, Aaron P. YAMNIUK, Derek A. HOLMES, Guodong CHEN, Priyanka Apurva MADIA, Richard Yu-Cheng HUANG, Stephen Michael CARL
  • Serum albumin-binding fibronectin type III domains
    Patent number: 11203630
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: December 21, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan H. Davis, David Fabrizio
  • Anti-TREM-1 antibodies and uses thereof
    Patent number: 11155618
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: October 26, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
  • Serum albumin binding molecules
    Patent number: 10934572
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: March 2, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
  • FAST-OFF RATE SERUM ALBUMIN BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20200283505
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: January 21, 2020
    Publication date: September 10, 2020
    Inventors: Stanley Richard KRYSTEK, JR., Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Juhi JUNEJA
  • Fast-off rate serum albumin binding fibronectin type III domains
    Patent number: 10766946
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 8, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stanley Richard Krystek, Jr., Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Juhi Juneja
  • SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20200048328
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: August 23, 2019
    Publication date: February 13, 2020
    Inventors: Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Rex PARKER, Ray CAMPHAUSEN, Jonathan DAVIS, David FABRIZIO
  • Serum albumin-binding fibronectin type III domains
    Patent number: 10442851
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: October 15, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan Davis, David Fabrizio
  • ANTI-TREM-1 ANTIBODIES AND USES THEREOF
    Publication number: 20190300608
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Application
    Filed: April 1, 2019
    Publication date: October 3, 2019
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia
  • SERUM ALBUMIN BINDING MOLECULES
    Publication number: 20190203248
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: January 10, 2019
    Publication date: July 4, 2019
    Inventors: Michael L. GOSSELIN, David FABRIZIO, Joanna F. SWAIN, Tracy MITCHELL, Ray CAMPHAUSEN, Sharon T. CLOAD, Eric FURFINE, Paul E. MORIN, Ranjan MUKHERJEE, Simeon I. TAYLOR
  • Serum albumin binding molecules
    Patent number: 10221438
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: March 5, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
  • FAST-OFF RATE SERUM ALBUMIN BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20180258158
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: September 22, 2016
    Publication date: September 13, 2018
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stanley Richard KRYSTEK, Jr., Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Juhi JUNEJA
  • SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20170174748
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: March 19, 2015
    Publication date: June 22, 2017
    Inventors: Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Rex PARKER, Ray CAMPHAUSEN, Jonathan DAVIS, David FABRIZIO
  • SERUM ALBUMIN BINDING MOLECULES
    Publication number: 20170145464
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: November 29, 2016
    Publication date: May 25, 2017
    Inventors: Michael L. GOSSELIN, David FABRIZIO, Joanna F. SWAIN, Tracy MITCHELL, Ray CAMPHAUSEN, Sharon T. CLOAD, Eric FURFINE, Paul E. MORIN, Ranjan MUKHERJEE, Simeon I. TAYLOR